AIGH Capital Management »

Kyverna Therapeutics shares owned by AIGH Capital Management

Quarter-by-quarter ownership of Kyverna Therapeutics (KYTX) shares owned by AIGH Capital Management from 13F filings

Historical chart of AIGH Capital Management investment in Kyverna Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kyverna Therapeutics held by AIGH Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kyverna Therapeutics by AIGH Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $14M 1.5M 9.40

More positions owned by AIGH Capital Management

Sandisk Corp (SNDK)
Zoom Communications Call Call Option
Castle Biosciences (CSTL)
Personalis Ord (PSNL)
Nlight (LASR)
Day One Biopharmaceuticals I (DAWN)
Vanda Pharmaceuticals (VNDA)
Bk Technologies Corporation Com New (BKTI)
Domo Com Cl B (DOMO)
Esperion Therapeutics (ESPR)
Kyverna Therapeutics (KYTX)
Fennec Pharmaceuticals (FENC)
Lightpath Technologies Com Cl A (LPTH)
Abeona Therapeutics Com New (ABEO)
Zevra Therapeutics Call Call Option

View all positions for AIGH Capital Management

Top funds holding Kyverna Therapeutics

Vida Ventures Advisors
Gilead Sciences
Bain Capital Life Sciences Investors
Vanguard Group
AIGH Capital Management
Insight Holdings
Franklin Resources
Mbb Public Markets I
Catalio Capital Management
Millennium Management
BlackRock
Kera Capital Partners
Geode Capital Management
Woodline Partners
Susquehanna International

View all funds holding Kyverna Therapeutics